Abcellera Biologics Inc ABCL

$13.15 -0.63 (-4.57%)

Valuation

Market cap
4,225,100,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
9,788,601
Avg volume
7,148,132
Day's range
$12.93 – $14.53
Shares out
306,611,000
Stochastic %K
42%
Beta
1.41
Analysts
Strong Sell
Price target
$16.70

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

SocioCobb Oct 6, 11:32 PM
$ABCL
1 replies
Plan2TradeTrade2Plan Oct 6, 7:54 PM
$ABCL sea of red today in some bios. $TWST down about $40, but has been the star.
1 replies
Rastafari Oct 6, 6:06 PM
$ABCL ABCL has certainly been in a consolidation phase for the past few weeks. It feels like a roller coaster at times, but this is normal as the stock establishes its new trading range and finds its new average. From here, I believe we’re setting up for a breakout. When earnings are announced in early November, we should see some significant movement. After that, it’s all about the progress of ABCL635 and any new partnerships the company announces. As we move into 2027, I believe ABCL’s new trading range will be above $20. Mark this post!
1 replies
villaspecialisten Oct 6, 5:20 PM
$ABCL boys. I usually am very quick on taking profits. But not here. On this one i hold tight. Thing is, this mf can blow up a couple hundred percent in a day or two with the right news.. but same thing applies the other way around. Invest money your ready to lose. Cause this could be the best or worst trade of your life. I never touch biotech, but ABCL got a convincing case going.
0 replies
PolarBear1 Oct 6, 5:01 PM
$ABCL More shorts escaping IMHO
0 replies
Baazigar123 Oct 6, 3:57 PM
$ABCL sector rotation
2 replies
FGA Oct 6, 3:53 PM
$ABCL 100%. I usually don't post more than a sentence or two, but these rich asshats and their puppets have been jerking this thing back and forth for a while now. 😂😭 Let them play their games. I’ve learned, that they can’t manipulate—PATIENCE. I’ve been in ABCL since it was down around $3. I’ve banked some nice profits along the way, added and traded around my position, and I’m still sitting on plenty of shares for what I believe could be the REAL payday. 💰 I do my own DD and usually keep it to myself! Nothing in biotech is guaranteed. But here’s what has me excited: ABCL does NOT need every program to become a blockbuster. Start getting successful drug candidates into the clinic, advancing through trials, and eventually reaching commercialization—and suddenly you’re talking milestones, royalties, and potentially multiple shots on goal. That’s when this story could get VERY interesting. So manipulate it. Short it. Shake the tree. Scare out the weak hands 😆 It's coming!💰🤑🔥
0 replies
Metacognitive_Drivel Oct 6, 2:39 PM
$ABCL drop a couple more points so I can buy again.
1 replies